Trial of Sorafenib in Hepatocellular Cancer (HCC) Transplant Patients

Summary

This Phase I study of sorafenib in high risk hepatocellular cancer patients after liver transplantation will study 24 subjects for about 5 years. Each subject will receive sorafenib for 6 months. Safety and effectiveness on the post transplant, high risk HCC patients will be studied.

Timeline

Start

2009-05

Primary completion

2015-05

Completion

2015-05

Drugs

Indications